Emgality (fremanezumab) is a migraine medication prescribed to reduce the number and severity of migraine attacks in adults. Although no single migraine treatment works for everyone, some people have ...
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results